Marc Zumberg, MD
Hematology & Oncology · Gainesville, FLNPI 1487691895
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,280 of the $20,658 with a category attached, or 93.3%. Sanofi accounts for 61.0% of it on its own, with 5 other manufacturers making up the rest. 2024 is the largest year on record at $11,753, 6.0 times the $1,965 reported in 2020.
Across 13 payments — averaging $1589.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$13K
- UCB SA$4K
- Janssen Global Services, LLC$2K
- Novartis$2K
- Astellas Pharma US Inc$95
- Pharmacyclics LLC, An Abbvie Company$74
Across 2 payments — averaging $5850.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$12K
What the payments were for
- Consulting fees$19,28093%
- Travel & lodging$8874%
- Food & beverage$3232%
- Education$1691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 6 | $12,604 |
| UCB SA | 3 | $3,900 |
| Janssen Global Services, LLC | 1 | $2,020 |
| Novartis | 1 | $1,965 |
| Astellas Pharma US Inc | 1 | $95 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,658 in reported general payments places this provider in the 70th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $48,262 |
| OxycontinOxycodone Hcl | 11 | $8,936 |
| Morphine Sulfate ErMorphine Sulfate | 77 | $3,492 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 46 | $1,340 |
| Oxycodone Hcl | 99 | $1,329 |
| Methadone Hcl | 15 | $700 |
| Hydroxyurea | 34 | $610 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Gainesville
- George KimGainesville$361K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.